ArticleDermatology and therapy2026
Dupilumab Improves Daily Symptom Burden in Adult Patients with Prurigo Nodularis: Post Hoc Analysis from LIBERTY PN-PRIME and PRIME2 Studies.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable
A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrurigo nodularis (PN/chronic prurigo) is characterised by intensely pruritic, symmetrically distributed nodules. In the PRIME (NCT04183335) and PRIME2 (NCT04202679) clinical trials, dupilumab demonstrated clinically meaningful and statistically significant improvements in itch versus placebo in patients with uncontrolled PN on topical therapies. This post hoc analysis evaluated the efficacy of dupilumab versus placebo in reducing the daily symptom burden (DSB) with respect to itch, skin pain, and sleep disturbance in patients with PN.
methodsPooled data from the PRIME and PRIME2 trials (N = 311) were utilised. DSB was assessed with three patient-reported outcomes (PROs): Worst Itch Numeric Rating Scale (WI-NRS), Skin Pain-NRS, and Sleep-NRS. Each PRO utilised a scale of 0-10 (0: no pruritus/no skin pain/worst possible sleep; 10: worst pruritus/worst skin pain/best possible sleep). The symptom intensity was categorised as no symptoms (0 for WI-NRS and Skin Pain-NRS; 10 for Sleep-NRS), mild (1-2 or 8-9), moderate (3-6 or 4-7), severe (7-8 or 2-3), and very severe (9-10 or 0-1). The proportion of patients experiencing only none-to-mild symptoms and the mean frequency of days with only such symptoms in the week before week 24 were compared between treatment arms.
resultsIn the week before week 24, significantly higher proportions of patients treated with dupilumab had only none-to-mild symptom days than those receiving placebo with respect to WI-NRS (26.8% vs 7.6%), Skin Pain-NRS (38.6% vs 19.0%), and Sleep-NRS (28.8% vs 10.1%), with p < 0.0001. At week 24, patients treated with dupilumab had more days per week with none-to-mild itch (mean 2.4 vs 0.9), skin pain (3.4 vs 1.9), and sleep disturbance (2.7 vs 1.4) versus placebo.
conclusionPatients treated with dupilumab showed greater improvement in DSB with respect to itch, skin pain, and sleep disturbance than those receiving placebo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.